NYSE:BHVNBiotechs
Assessing Biohaven (BHVN) Valuation After Pipeline Optimism And Supportive Sector Sentiment
Why Biohaven is back on traders' screens
Biohaven (BHVN) is back in focus after upbeat analyst commentary on its epilepsy drug opakalim, stronger sentiment following a peer’s Phase 3 epilepsy result, and a sector wide reaction to US regulatory leadership changes.
See our latest analysis for Biohaven.
Despite a positive 1 day share price return of 0.59% to US$10.27 after the recent analyst commentary and sector tailwinds, Biohaven’s 30 day share price return of 11.47% and 1 year total...